How are Structure Therapeutics Ordinary Shares and ADSs related in this Form 4?

The Form 4 explains that Structure Therapeutics’ Ordinary Shares may be represented by American Depositary Shares. Each ADS represents three Ordinary Shares, meaning any ADS trading activity in the market reflects this three-to-one relationship with the underlying Ordinary Shares.

Structure Therapeutics director granted 39,453 options

Structure Therapeutics Inc. director Daniel G. Welch received a grant of share options covering 39,453 Ordinary Shares at an exercise price of $15.00 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Structure Therapeutics Inc. director Daniel G. Welch received a grant of share options covering 39,453 Ordinary Shares at an exercise price of $15.00 per share. The options vest in equal monthly installments over the 12 months following June 17, 2026, and will in any case be fully vested immediately before the company’s 2027 annual shareholder meeting. Following this grant, Welch holds 39,453 share options directly, each relating to Ordinary Shares that may be represented by American Depositary Shares, with each ADS representing three Ordinary Shares.

Insider Trade Summary

Grant/Award: 39,453 shares

Grant/Award 1 txn

Insider WELCH DANIEL G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	39,453	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 39,453 contracts (Direct)

Footnotes (3)

F1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2. The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Key Figures

Option grant size: 39,453 options Exercise price: $15.00 per share Post-grant option holdings: 39,453 options +3 more

6 metrics

Option grant size 39,453 options Share Option (right to buy) granted to director

Exercise price <money>$15.00</money> per share Equal to fair market value on grant date

Post-grant option holdings 39,453 options Total derivative securities following transaction

Option expiration date <date>June 16, 2036</date> Expiration of granted share options

Vesting period 12 months Equal monthly vesting after June 17, 2026

ADS to Ordinary Share ratio 1 ADS = 3 Ordinary Shares Representation of Ordinary Shares by ADSs

Key Terms

Share Option (right to buy), American Depositary Shares ("ADSs"), fair market value, annual shareholder meeting

4 terms

American Depositary Shares ("ADSs") financial

"based on the trading price of the Issuer's American Depositary Shares ("ADSs")."

American Depositary Shares (ADSs) are U.S.-listed certificates issued by a bank that represent ownership of a specified number of a foreign company’s ordinary shares, letting U.S. investors buy and sell those interests in U.S. dollars on American markets. They matter because they make investing in overseas companies as easy as buying a domestic stock—streamlining currency, settlement, and recordkeeping—while still exposing investors to foreign-market risks like exchange rates and local regulations.

fair market value financial

"exercise price per share is equal to the fair market value per Ordinary Share"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

annual shareholder meeting financial

"fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting"

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Daniel G. Welch report in this Form 4 for Structure Therapeutics (GPCR)?

Daniel G. Welch reported receiving a grant of options to buy 39,453 Ordinary Shares of Structure Therapeutics. These options were granted as a compensation award and are recorded as a derivative security with an exercise price set at the fair market value on the grant date.

What is the exercise price and size of the new option grant at Structure Therapeutics (GPCR)?

The new option grant covers 39,453 Ordinary Shares with an exercise price of $15.00 per share. The filing notes this price equals the fair market value per Ordinary Share on the grant date, based on the trading price of the company’s American Depositary Shares.

How do the granted options to Daniel G. Welch at GPCR vest over time?

The options vest in equal monthly installments over the 12 months following June 17, 2026. The filing also states the grant will be fully vested immediately before Structure Therapeutics’ 2027 annual shareholder meeting, whichever timing ensures complete vesting by that point.

When do Daniel G. Welch’s Structure Therapeutics options expire?

The options granted to Daniel G. Welch expire on June 16, 2036. This long-dated expiration gives him a substantial period to exercise the right to purchase the underlying Ordinary Shares once they have vested according to the specified monthly vesting schedule.

How many options does Daniel G. Welch hold after this transaction in GPCR?

After this grant, Daniel G. Welch holds 39,453 share options directly. Each option relates to one Ordinary Share of Structure Therapeutics, and the filing indicates these Ordinary Shares may be represented by American Depositary Shares listed and traded in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 05:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WELCH DANIEL G

(Last)

(First)

(Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (right to buy)	$15⁽¹⁾	06/17/2026		A		39,453		⁽²⁾	06/16/2036	Ordinary Shares	39,453⁽³⁾	$0	39,453	D

Explanation of Responses:

1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

2. The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,

3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

	/s/ Jun Yoon, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR